CLAIMS

Claim 1

An oral pharmaceutical composition in the form of a dry syrup comprising: ART-001 (serabelisib); phosphoric acid; and povidone.

Claim 2

The oral pharmaceutical composition according to claim 1, further comprising one or more acids selected from hydrochloric acid, citric acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, succinic acid, aspartic acid, lactic acid, acetic acid, glutamic acid, and adipic acid.

Claim 3

The oral pharmaceutical composition according to claim 1 or 2, further comprising one or more polymers selected from polyvinyl alcohol, hypromellose, copovidone, hydroxypropylcellulose, polyvinyl alcohol-polyethylene glycol-graft copolymer, hypromellose phthalate, and hypromellose acetate succinate.

Claim 4

The oral pharmaceutical composition according to any one of claims 1 to 3, wherein the content percentage of ART-001 (serabelisib) is from 2 to 40 mass %.

Claim 5

The oral pharmaceutical composition according to any one of claims 1 to 4, wherein the content ratio of the phosphoric acid and any further acid to one mass part of ART-001 (serabelisib) is from 0.1 to 10 mass parts.

Claim 6

The oral pharmaceutical composition according to any one of claims 1 to 5, wherein the content ratio of povidone and any further polymer to one mass part of ART-001 (serabelisib) is from 0.02 to 5 mass parts.

Claim 7

A method of producing an oral pharmaceutical composition according to any one of claims 1 to 6, comprising:

wet-granulating a mixture containing ART-001 (serabelisib), phosphoric acid, and povidone; and

drying the granulated product.